Iowanews Headlines

DelveInsight’s, “BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the BRAF + NSCLC Pipeline? Click here to explore the therapies and trials making headlines @ BRAF + NSCLC Pipeline Outlook Report

Key Takeaways from the BRAF + NSCLC Pipeline Report

• In June 2025, Pierre Fabre Medicament conducted a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naïve and are either previously untreated or have had one line of prior therapy in metastatic setting.
• DelveInsight’s BRAF + NSCLC Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF + NSCLC treatment.
• The leading BRAF + NSCLC Companies such as Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, and others.
• Promising BRAF+NSCLC Therapies such as HLX208+HLX10, VS-6766, GSK1120212, Docetaxel, Dabrafenib, Trametinib, encorafenib, binimetinib, MPDL3280A, Vemurafenib, Alectinib and others.

Want to know which companies are leading innovation in BRAF + NSCLC? Dive into the full pipeline insights @ BRAF + NSCLC Clinical Trials Assessment

The BRAF + NSCLC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The BRAF + NSCLC Pipeline Report also highlights the unmet needs with respect to the BRAF + NSCLC.

BRAF + NSCLC Overview

BRAF mutated lung cancer is a rare form of NSCLC. BRAF mutations have been reported in about 4% of non-small cell lung cancers (NSCLC). They are most common in adenocarcinoma non-small cell lung cancer. BRAF V600E mutations specifically occur in about 1-2% of non-small cell lung cancer patients. Most patients with BRAF V600E tend to have a smoking history.

BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs

• Encorafenib/Binimetinib: Pierre Fabre Medicament

BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.

XP-102: Xynomic Pharmaceuticals, Inc.

XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.

If you’re tracking ongoing BRAF + NSCLC Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ BRAF + NSCLC Treatment Drugs

BRAF + NSCLC Companies

Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, and others.

The BRAF + NSCLC Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of BRAF + NSCLC with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BRAF + NSCLC Treatment.
• BRAF + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• BRAF + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BRAF + NSCLC market.

BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

BRAF + NSCLC Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the BRAF + NSCLC Pipeline Report covers it all – check it out now @ BRAF + NSCLC Market Drivers and Barriers, and Future Perspectives

Scope of the BRAF + NSCLC Pipeline Report

• Coverage- Global
• BRAF + NSCLC Companies- Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, and others.
• BRAF+NSCLC Therapies- HLX208+HLX10, VS-6766, GSK1120212, Docetaxel, Dabrafenib, Trametinib, encorafenib, binimetinib, MPDL3280A, Vemurafenib, Alectinib and others.
• BRAF + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• BRAF + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the BRAF + NSCLC treatment landscape in this detailed analysis @ BRAF + NSCLC Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. BRAF-mutant Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Encorafenib/Binimetinib: Pierre Fabre Medicament
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. XP-102: Xynomic Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
21. BRAF-mutant Non-Small Cell Lung Cancer Key Products
22. BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
26. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services